CN111840763A - Liquid conveying device and treatment device - Google Patents
Liquid conveying device and treatment device Download PDFInfo
- Publication number
- CN111840763A CN111840763A CN202010833882.5A CN202010833882A CN111840763A CN 111840763 A CN111840763 A CN 111840763A CN 202010833882 A CN202010833882 A CN 202010833882A CN 111840763 A CN111840763 A CN 111840763A
- Authority
- CN
- China
- Prior art keywords
- chamber
- liquid
- pressure
- delivery port
- delivery device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 162
- 230000007246 mechanism Effects 0.000 claims abstract description 92
- 238000007789 sealing Methods 0.000 claims abstract description 52
- 230000000903 blocking effect Effects 0.000 claims abstract description 40
- 239000006185 dispersion Substances 0.000 claims abstract description 40
- 239000002270 dispersing agent Substances 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims description 111
- 239000012530 fluid Substances 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 6
- 238000003825 pressing Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000011109 contamination Methods 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 description 40
- 238000010586 diagram Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 229940126589 solid medicine Drugs 0.000 description 5
- 238000004891 communication Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical compound C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- YLKVIMNNMLKUGJ-FPLPWBNLSA-N (15:1)-Cardanol Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-FPLPWBNLSA-N 0.000 description 1
- YFESOSRPNPYODN-RSMWSHJLSA-N (2s,3s,4s,5r,6r)-6-[[(4s,6ar,6bs,8r,8ar,9r,10r,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2s,3r,4s, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFESOSRPNPYODN-RSMWSHJLSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- YLKVIMNNMLKUGJ-UHFFFAOYSA-N 3-Delta8-pentadecenylphenol Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229940123056 Thymidine kinase inhibitor Drugs 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 229940124605 anti-osteoporosis drug Drugs 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- BOFZOTMTKBQRAB-UHFFFAOYSA-N azanium;2-carboxyphenolate Chemical compound N.OC(=O)C1=CC=CC=C1O BOFZOTMTKBQRAB-UHFFFAOYSA-N 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 description 1
- 229940079488 strontium ranelate Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 239000003803 thymidine kinase inhibitor Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229950009819 zotarolimus Drugs 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M29/00—Dilators with or without means for introducing media, e.g. remedies
- A61M29/02—Dilators made of swellable material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1086—Balloon catheters with special features or adapted for special applications having a special balloon surface topography, e.g. pores, protuberances, spikes or grooves
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
本发明涉及一种液体输送装置及治疗装置,液体输送装置包括壳体,具有内腔,壳体上设有与内腔连通的输送口,输送口用于与外部机构连通;壳体的内腔中形成有存储液体分散剂的第一腔室和存储分散质的第二腔室,第二腔室与输送口连通;第一阀门,控制第一腔室与第二腔室间的通断;第一封堵部,控制输送口与外部机构间的通断;压力施加机构。当第一阀门开启,且第一封堵部封堵输送口后,第一腔室和第二腔室连通,使液体分散剂进入第二腔室并与分散质混合形成分散系;当解除第一封堵部对输送口的封堵后,压力施加机构施加压力,第二腔室中的分散系流至外部机构,并从外部机构流出。该液体输送装置可依次完成分散系的配置和输送,避免对分散系造成污染。
The invention relates to a liquid delivery device and a treatment device. The liquid delivery device comprises a casing with an inner cavity, the casing is provided with a delivery port communicating with the inner cavity, and the delivery port is used to communicate with an external mechanism; A first chamber for storing liquid dispersant and a second chamber for storing dispersoid are formed in the middle, and the second chamber is communicated with the delivery port; the first valve controls the on-off between the first chamber and the second chamber; The first sealing part controls the on-off between the delivery port and the external mechanism; the pressure applying mechanism. When the first valve is opened and the first blocking part blocks the delivery port, the first chamber and the second chamber are connected, so that the liquid dispersant enters the second chamber and mixes with the dispersoid to form a dispersion system; After the delivery port is blocked by the blocking portion, the pressure applying mechanism applies pressure, and the dispersion system in the second chamber flows to and from the external mechanism. The liquid conveying device can complete the configuration and conveying of the dispersion system in sequence, so as to avoid contamination of the dispersion system.
Description
技术领域technical field
本发明涉及医疗器械技术领域,具体涉及一种液体输送装置及治疗装置。The invention relates to the technical field of medical devices, in particular to a liquid delivery device and a treatment device.
背景技术Background technique
自上世纪70年代以来,介入类医疗器械在各种心血管疾病的治疗方面得到了广泛的应用,并经历了单纯球囊扩张(PTCA)、裸金属支架(BMS)及药物洗脱支架(DES)三个里程碑式的快速发展阶段。目前,DES是阻塞性冠心病的首选治疗方案,但其存在晚期支架内血栓、血管愈合时间长、易影响血管动脉等问题,且支架内在狭窄(ISR)、小血管病变和分叉病变等也限制了DES的应用。在此情况下,药物涂层球囊(DCB)应运而生,并显示出较好的治疗效果。Since the 1970s, interventional medical devices have been widely used in the treatment of various cardiovascular diseases, and have experienced simple balloon dilatation (PTCA), bare metal stents (BMS) and drug-eluting stents (DES). ) three milestone stages of rapid development. At present, DES is the first choice for the treatment of obstructive coronary heart disease, but it has problems such as late stent thrombosis, long vascular healing time, and easy influence on vascular arteries. In-stent stenosis (ISR), small vessel disease and bifurcation disease also Limits the application of DES. Under this circumstance, drug-coated balloon (DCB) came into being and showed better therapeutic effect.
现有技术中的药物球囊大多是将抗增生药物涂覆在球囊的表面,使用时先将球囊推送至病变处,然后扩张球囊以释放药物。这种设计的药物球囊存在如下缺陷:(1)在推送球囊的过程中,药物易脱落损失,造成药物剂量不足,甚至脱落的药物还会引起毒副作用;(2)药物球囊表面涂覆的药物在扩张时容易形成大的药物颗粒,极可能引发远端血管栓塞,具有较高的安全风险;(3)药物剂量不可控,且一个球囊只能用于一个部位。Most of the drug balloons in the prior art coat the surface of the balloon with anti-proliferative drugs. When in use, the balloon is first pushed to the lesion, and then the balloon is expanded to release the drug. The drug balloon of this design has the following defects: (1) During the process of pushing the balloon, the drug is easy to fall off and lose, resulting in insufficient drug dose, and even the fallen drug may cause toxic and side effects; (2) The surface of the drug balloon is coated with The covered drug is likely to form large drug particles during expansion, which is likely to cause distal vascular embolism and has a high safety risk; (3) the drug dose is uncontrollable, and one balloon can only be used for one site.
针对上述缺陷,目前市面上出现了灌注药物球囊,即将液体药剂注入球囊,之后液体药剂从球囊壁上的微孔流出后被病变组织吸收。虽然灌注药物球囊解决了药物涂层球囊存在的一些缺陷,但灌注药物球囊仍存在药剂配置后转移至球囊的过程繁琐不易控制,以及配置药剂、转移药剂时药剂易污染的问题。In view of the above-mentioned defects, a drug perfusion balloon is currently available on the market, that is, a liquid drug is injected into the balloon, and then the liquid drug flows out of the micropores on the balloon wall and is absorbed by the diseased tissue. Although the perfusion drug balloon solves some of the defects of the drug-coated balloon, the perfusion drug balloon still has the problem that the process of transferring the medicine to the balloon after preparation is cumbersome and difficult to control, and the medicine is easily contaminated during preparation and transfer of the medicine.
发明内容SUMMARY OF THE INVENTION
本发明的目的在于提供一种液体输送装置及治疗装置,该液体输送装置可在完成药剂配置后直接将药剂转移至球囊中,简化药剂转移的过程,也无需额外采用其他中间容器,避免污染药剂。The purpose of the present invention is to provide a liquid delivery device and a treatment device. The liquid delivery device can directly transfer the medicament into the balloon after completing the medicament configuration, which simplifies the process of medicament transfer, and does not require additional intermediate containers to avoid contamination. Pharmacy.
为实现上述目的,本发明提供了一种液体输送装置,包括:In order to achieve the above object, the present invention provides a liquid delivery device, comprising:
壳体,具有内腔,所述壳体上设有与所述内腔连通的输送口,所述输送口用于与外部机构连通;所述壳体的内腔中形成有第一腔室和第二腔室,所述第一腔室用于存储液体分散剂,所述第二腔室用于存储分散质,所述第二腔室与所述输送口连通;a casing with an inner cavity, the casing is provided with a delivery port communicating with the inner cavity, and the delivery port is used to communicate with an external mechanism; a first chamber and a first chamber are formed in the inner cavity of the casing a second chamber, the first chamber is used to store the liquid dispersant, the second chamber is used to store the dispersant, and the second chamber is communicated with the delivery port;
第一阀门,用于控制所述第一腔室与所述第二腔室间的通断;a first valve for controlling the on-off between the first chamber and the second chamber;
第一封堵部,用于控制所述输送口与所述外部机构间的通断;以及,a first blocking part for controlling the on-off between the delivery port and the external mechanism; and,
压力施加机构;pressure applying mechanism;
所述液体输送装置被配置为当所述第一阀门开启,以及所述第一封堵部封堵所述输送口后,所述第一腔室和所述第二腔室连通,使所述液体分散剂进入所述第二腔室并与所述分散质混合而形成分散系;The liquid delivery device is configured such that when the first valve is opened and the delivery port is blocked by the first blocking portion, the first chamber and the second chamber are communicated, so that the a liquid dispersant enters the second chamber and mixes with the dispersoid to form a dispersion;
所述液体输送装置还被配置为当解除所述第一封堵部对所述输送口的封堵后,所述压力施加机构施加压力,使所述第二腔室中的分散系通过所述输送口流至所述外部机构。The liquid delivery device is further configured such that the pressure applying mechanism applies pressure to allow the dispersion system in the second chamber to pass through the delivery port after the first blocking portion is released from blocking the delivery port. The delivery port flows to the external mechanism.
可选地,所述压力施加机构设置在所述第一腔室中,并被配置为施加压力至第一预定值后,使所述第一阀门开启。Optionally, the pressure applying mechanism is provided in the first chamber, and is configured to open the first valve after applying pressure to a first predetermined value.
可选地,所述第一阀门为单向阀,所述单向阀被配置为在受到从所述第一腔室指向所述第二腔室的第一预定值的压力后开启,而在受到从所述第二腔室指向所述第一腔室的压力时保持关闭。Optionally, the first valve is a one-way valve configured to open after being subjected to a first predetermined value of pressure directed from the first chamber to the second chamber, and is It remains closed when subjected to pressure directed from the second chamber to the first chamber.
可选地,所述第一阀门包括阀座、第一封板和第一弹性件,所述阀座设置在一分割机构上,所述分割机构用于将所述内腔分割为所述第一腔室和所述第二腔室;且所述阀座上开设有轴向贯通的流体通道,所述流体通道的壁上设置有台阶面;所述第一弹性件设置在所述流体通道内,所述第一弹性件的一端与所述流体通道的壁连接,另一端与所述第一封板连接;Optionally, the first valve includes a valve seat, a first sealing plate and a first elastic member, the valve seat is arranged on a dividing mechanism, and the dividing mechanism is used to divide the inner cavity into the first a chamber and the second chamber; and the valve seat is provided with an axially through fluid channel, and the wall of the fluid channel is provided with a stepped surface; the first elastic member is arranged on the fluid channel inside, one end of the first elastic member is connected with the wall of the fluid channel, and the other end is connected with the first sealing plate;
所述第一封板在所述第一弹性件的作用下抵靠在所述台阶面上以关闭所述流体通道;所述第一封板受到从所述第一腔室指向所述第二腔室的所述第一预定值的压力时,所述第一弹性件变形以使所述第一封板脱离所述台阶面而开启所述流体通道。The first sealing plate abuts against the step surface under the action of the first elastic member to close the fluid channel; the first sealing plate is directed from the first chamber to the second When the pressure of the chamber is at the first predetermined value, the first elastic member is deformed so that the first sealing plate is separated from the step surface and the fluid channel is opened.
可选地,所述压力施加机构包括第一活塞,所述第一活塞被配置为外力的作用下朝向所述第二腔室方向移动,使所述第一阀门开启。Optionally, the pressure applying mechanism includes a first piston, and the first piston is configured to move toward the second chamber under the action of an external force, so that the first valve is opened.
可选地,还包括分割机构,用于将所述内腔分割为所述第一腔室和所述第二腔室,所述第一阀门设置在所述分割机构上。Optionally, a dividing mechanism is further included for dividing the inner cavity into the first chamber and the second chamber, and the first valve is arranged on the dividing mechanism.
可选地,所述分割机构包括第二活塞;Optionally, the dividing mechanism includes a second piston;
所述压力施加机构用于向所述第二活塞施加压力,以驱动所述第二活塞移动而向所述分散系施加压力。The pressure applying mechanism is used for applying pressure to the second piston to drive the second piston to move and apply pressure to the dispersion system.
可选地,还包括第二封堵部,设置在所述输送口处,用于在所述分散系受到的压力值超过第二预定值时封堵所述输送口。Optionally, a second blocking part is further included, which is arranged at the delivery port and is used to block the delivery port when the pressure value received by the dispersion system exceeds a second predetermined value.
可选地,所述第二封堵部包括第二封板和第二弹性件,所述第二弹性件的一端与所述第二封板连接,另一端与所述壳体连接;Optionally, the second blocking portion includes a second sealing plate and a second elastic member, one end of the second elastic member is connected to the second sealing plate, and the other end is connected to the housing;
所述第二活塞向所述分散系施加压力,进而向所述第二封板施加压力,所述第二封堵部被配置为,当所述第二封板受到的压力小于等于所述第二预定值时,所述第二弹性件支撑所述第二封板,以使所述第二封板远离所述输送口而保持所述输送口开启;当所述第二封板受到的压力大于所述第二预定值时,所述第二弹性件变形以使所述第二封板朝向所述输送口移动,以封堵所述输送口。The second piston applies pressure to the dispersion system, and further applies pressure to the second sealing plate, and the second blocking portion is configured to, when the pressure received by the second sealing plate is less than or equal to the first sealing plate. When there are two predetermined values, the second elastic member supports the second sealing plate, so as to keep the second sealing plate away from the conveying port and keep the conveying port open; when the pressure of the second sealing plate When the value is greater than the second predetermined value, the second elastic member is deformed to move the second sealing plate toward the delivery port, so as to block the delivery port.
可选地,所述压力施加机构还包括推杆,设置在所述第一活塞远离所述分割机构的一端,用于接受外力并驱动所述第一活塞移动。Optionally, the pressure applying mechanism further includes a push rod disposed at one end of the first piston away from the dividing mechanism, for receiving external force and driving the first piston to move.
可选地,所述第一封堵部包括第二阀门,所述液体输送装置还包括压力控制机构;Optionally, the first blocking part includes a second valve, and the liquid delivery device further includes a pressure control mechanism;
所述压力控制机构被配置为监测所述分散系受到的压力,且当所述分散系受到的压力超过第二预定值时控制所述第二阀门封堵所述输送口。The pressure control mechanism is configured to monitor the pressure to which the dispersion system is subjected, and to control the second valve to block the delivery port when the pressure to which the dispersion system is subjected exceeds a second predetermined value.
可选地,还包括过滤机构,设置在所述输送口处。Optionally, a filter mechanism is also included, which is arranged at the delivery port.
可选地,所述输送口处设置有鲁尔接头,用于与所述外部机构可拆卸地连接。Optionally, a luer connector is provided at the delivery port for detachable connection with the external mechanism.
为实现上述目的,本发明还提供了一种治疗装置,包括:In order to achieve the above object, the present invention also provides a treatment device, comprising:
如前任一项所述的液体输送装置;A liquid delivery device as described in any preceding item;
液体分散剂,设置在所述第一腔室中;a liquid dispersant, disposed in the first chamber;
固体药剂,设置在所述第二腔室中;a solid medicament, disposed in the second chamber;
球囊导管,包括导管和球囊,所述导管的一端与所述球囊连通,另一端用于与所述液体输送装置的输送口连通,且所述球囊上设置有多个微孔。A balloon catheter includes a catheter and a balloon, one end of the catheter is communicated with the balloon, the other end is used to communicate with the delivery port of the liquid delivery device, and the balloon is provided with a plurality of micropores.
可选地,所述微孔在所述球囊的近端的分布密度小于所述微孔在所述球囊的远端的分布密度;和/或,Optionally, the distribution density of the micropores at the proximal end of the balloon is less than the distribution density of the micropores at the distal end of the balloon; and/or,
设置在所述球囊的近端的微孔的孔径小于设置在所述球囊的远端的微孔的孔径。The diameter of the micropores provided at the proximal end of the balloon is smaller than the diameter of the micropores provided at the distal end of the balloon.
可选地,所述微孔的孔径为5um-50um。Optionally, the diameter of the micropores is 5um-50um.
可选地,所述分散质分散于所述液体分散剂中形成悬浮液,所述悬浮液中的颗粒尺寸为30nm-500nm。Optionally, the dispersoid is dispersed in the liquid dispersant to form a suspension, and the particle size in the suspension is 30nm-500nm.
与现有技术相比,本发明的液体输送装置及治疗装置具有如下优点:Compared with the prior art, the liquid delivery device and the treatment device of the present invention have the following advantages:
第一、前述的液体输送装置包括:壳体,具有内腔,所述壳体上设有与所述内腔连通的输送口,所述输送口用于与外部机构连通;所述壳体的内腔中形成有第一腔室和第二腔室,所述第一腔室用于存储液体分散剂,所述第二腔室用于存储分散质,所述第二腔室与所述输送口连通;第一阀门,用于控制所述第一腔室与所述第二腔室间的通断;第一封堵部,用于控制述输送口与所述外部机构间的通断;以及,压力施加机构。所述液体输送装置被配置为当所述第一阀门开启,以及所述第一封堵部封堵所述输送口后,所述第一腔室和所述第二腔室连通,使所述液体分散剂进入所述第二腔室并与所述分散质混合而形成分散系。所述液体输送装置还被配置为当解除所述第一封堵部对所述输送口的封堵后,所述压力施加机构施加压力,使所述第二腔室中的分散系通过所述输送口流至所述外部机构,并进一步从所述外部机构流出。也就是说,在所述液体输送装置中可依次完成分散系的配置及分散系的输送,无需额外引入其他容器,避免分散系在输送过程中被污染。First, the aforementioned liquid conveying device includes: a casing with an inner cavity, the casing is provided with a conveying port communicating with the inner cavity, and the conveying port is used for communicating with an external mechanism; A first chamber and a second chamber are formed in the inner cavity, the first chamber is used to store the liquid dispersant, the second chamber is used to store the dispersoid, and the second chamber is connected with the delivery The first valve is used to control the connection between the first chamber and the second chamber; the first blocking part is used to control the connection between the delivery port and the external mechanism; And, the pressure applying mechanism. The liquid delivery device is configured such that when the first valve is opened and the delivery port is blocked by the first blocking portion, the first chamber and the second chamber are communicated, so that the A liquid dispersant enters the second chamber and mixes with the dispersoid to form a dispersion. The liquid delivery device is further configured such that the pressure applying mechanism applies pressure to allow the dispersion system in the second chamber to pass through the delivery port after the first blocking portion is released from blocking the delivery port. A delivery port flows to and from the external mechanism. That is to say, the configuration of the dispersion system and the transportation of the dispersion system can be completed in sequence in the liquid conveying device, without additionally introducing other containers, and avoiding the contamination of the dispersion system during the conveying process.
附图说明Description of drawings
附图用于更好地理解本发明,不构成对本发明的不当限定。其中:The accompanying drawings are used for better understanding of the present invention and do not constitute an improper limitation of the present invention. in:
图1是本发明根据一实施例所提供的液体输送装置的结构示意图;FIG. 1 is a schematic structural diagram of a liquid delivery device according to an embodiment of the present invention;
图2是本发明根据一实施例所提供的治疗装置的结构示意图;FIG. 2 is a schematic structural diagram of a treatment device according to an embodiment of the present invention;
图3是本发明根据一实施例所提供的液体输送装置的第一阀门的结构示意图,图示中的第一阀门为单向阀;3 is a schematic structural diagram of a first valve of a liquid delivery device according to an embodiment of the present invention, and the first valve in the illustration is a one-way valve;
图4是本发明根据一实施例所提供的液体输送装置的结构示意图,图示中的第一阀门与图1所示的液体输送装置的第一阀门不同;4 is a schematic structural diagram of a liquid delivery device according to an embodiment of the present invention, and the first valve in the illustration is different from the first valve of the liquid delivery device shown in FIG. 1;
图5是本发明根据另一实施例所提供的液体输送装置的结构示意图;5 is a schematic structural diagram of a liquid delivery device according to another embodiment of the present invention;
图6是本发明根据再一实施例所提供的液体输送装置的结构示意图,图示中第二封堵部的第二封板未封堵输送口;6 is a schematic structural diagram of a liquid delivery device provided by the present invention according to still another embodiment, in which the second sealing plate of the second blocking portion does not block the delivery port;
图7是图6所示的液体输送装置中第二封堵部的第二封板封堵输送口时的结构示意图;7 is a schematic structural diagram of the second sealing plate of the second blocking portion in the liquid delivery device shown in FIG. 6 when the delivery port is blocked;
图8是本发明根据一实施例所提供的治疗装置的球囊导管的局部结构示意图。FIG. 8 is a partial structural schematic diagram of a balloon catheter of a treatment device according to an embodiment of the present invention.
[附图标记说明如下]:[reference numerals are explained below]:
100-液体输送装置;100 - liquid delivery device;
110-壳体;110 - shell;
111-输送口,112-第一腔室,113-第二腔室;111-delivery port, 112-first chamber, 113-second chamber;
120-第二活塞;120 - the second piston;
130-第一阀;130 - the first valve;
131-阀座,132-第一封板,133-第一弹性件,134-流体通道,135-连接杆,136-密封块;131- valve seat, 132- first sealing plate, 133- first elastic piece, 134- fluid channel, 135- connecting rod, 136- sealing block;
140-第一封堵部;140 - the first blocking part;
150-压力施加机构;150 - pressure applying mechanism;
151-第一活塞,152-推杆;151 - first piston, 152 - push rod;
160-过滤机构;160 - filter mechanism;
170-第二封堵部;170-Second blocking part;
171-第二封板,172-第二弹性件;171 - the second cover plate, 172 - the second elastic part;
200-球囊导管;200-balloon catheter;
210-球囊;210-balloon;
211-微孔;211 - Micropore;
220-导管;220 - catheter;
300-液体分散剂;300 - liquid dispersant;
400-固体药剂;400 - solid medicine;
500-液体药剂。500 - Liquid Elixir.
具体实施方式Detailed ways
以下通过特定的具体实例说明本发明的实施方式,本领域技术人员可由本说明书所揭露的内容轻易地了解本发明的其他优点与功效。本发明还可以通过另外不同的具体实施方式加以实施或应用,本说明书中的各项细节也可以基于不同观点与应用,在没有背离本发明的精神下进行各种修饰或改变。需要说明的是,本实施例中所提供的图示仅以示意方式说明本发明的基本构想,遂图式中仅显示与本发明中有关的组件而非按照实际实施时的组件数目、形状及尺寸绘制,其实际实施时各组件的型态、数量及比例可为一种随意的改变,且其组件布局型态也可能更为复杂。The embodiments of the present invention are described below through specific specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and various details in this specification can also be modified or changed based on different viewpoints and applications without departing from the spirit of the present invention. It should be noted that the drawings provided in this embodiment are only to illustrate the basic concept of the present invention in a schematic way, so the drawings only show the components related to the present invention rather than the number, shape and the number of components in actual implementation. For dimension drawing, the type, quantity and proportion of each component can be changed at will in actual implementation, and the component layout may also be more complicated.
另外,以下说明内容的各个实施例分别具有一或多个技术特征,然此并不意味着使用本发明者必需同时实施任一实施例中的所有技术特征,或仅能分开实施不同实施例中的一部或全部技术特征。换句话说,在实施为可能的前提下,本领域技术人员可依据本发明的公开内容,并视设计规范或实作需求,选择性地实施任一实施例中部分或全部的技术特征,或者选择性地实施多个实施例中部分或全部的技术特征的组合,借此增加本发明实施时的弹性。In addition, each embodiment of the following description has one or more technical features, but this does not mean that the person using the present invention must implement all the technical features in any embodiment at the same time, or can only implement different embodiments separately. One or all of the technical features of the . In other words, under the premise of possible implementation, those skilled in the art can selectively implement some or all of the technical features in any embodiment according to the disclosure of the present invention and depending on design specifications or implementation requirements, or The combination of some or all of the technical features in the multiple embodiments is selectively implemented, thereby increasing the flexibility of the implementation of the present invention.
如在本说明书中所使用的,单数形式“一”、“一个”以及“该”包括复数对象,复数形式“多个”包括两个以上的对象,除非内容另外明确指出外。如在本说明书中所使用的,术语“或”通常是以包括“和/或”的含义而进行使用的,除非内容另外明确指出外,以及术语“安装”、“相连”、“连接”应做广义理解,例如,可以是固定连接,也可以是可拆卸连接,或一体地连接。可以是机械连接,也可以是电连接。可以是直接相连,也可以通过中间媒介间接相连,可以是两个元件内部的连通或两个元件的相互作用关系。对于本领域的普通技术人员而言,可以根据具体情况理解上述术语在本发明中的具体含义。此外,本文中,“近端”、“远端”是从使用该医疗装置的医生的角度来看各个元件相对于彼此的方位、位置,尽管“近端”、“远端”是非限制性的,但通常“近端”是指靠近医生的一端,“远端”是指首先进入患者体内的一端。As used in this specification, the singular forms "a," "an," and "the" include plural referents, and the plural forms "a plurality" include two or more referents unless the content clearly dictates otherwise. As used in this specification, the term "or" is generally employed in its sense including "and/or" unless the content clearly dictates otherwise, and the terms "installed", "connected", "connected" shall be To be understood in a broad sense, for example, it may be a fixed connection, a detachable connection, or an integral connection. It can be a mechanical connection or an electrical connection. It can be directly connected, or indirectly connected through an intermediate medium, and it can be the internal communication between two elements or the interaction relationship between the two elements. For those of ordinary skill in the art, the specific meanings of the above terms in the present invention can be understood according to specific situations. Also, herein, "proximal" and "distal" refer to the orientation, position of the various elements relative to each other from the perspective of the physician using the medical device, although "proximal" and "distal" are non-limiting , but usually "proximal" refers to the end that is closer to the doctor, and "distal" refers to the end that first enters the patient's body.
本发明的目的之一在于提供一种液体输送装置,包括壳体、第一阀门、第一封堵部和压力施加机构。其中,所述壳体具有内腔,所述壳体上设有与所述内腔连通的输送口,所述输送口用于与外部机构连通。所述壳体的内腔中形成有第一腔室和第二腔室,所述第一腔室用于存储液体分散剂,所述第二腔室用于存储分散质,所述第二腔室与所述输送口连通。所述第一阀门用于控制所述第一腔室与所述第二腔室间的通断。所述第一封堵部用于控制述输送口与所述外部机构间的通断。所述液体输送装置被配置为当所述第一阀门开启,以及所述第一封堵部封堵所述输送口后,所述第一腔室和所述第二腔室连通,使所述液体分散剂进入所述第二腔室并与所述分散质混合而形成分散系。所述液体输送装置还被配置为当解除所述第一封堵部对所述输送口的封堵后,所述压力施加机构施加压力,使所述第二腔室中的分散系通过所述输送口流至所述外部机构,并进一步从所述外部机构流出。One of the objectives of the present invention is to provide a liquid delivery device, which includes a housing, a first valve, a first blocking part and a pressure applying mechanism. Wherein, the housing has an inner cavity, and the housing is provided with a delivery port communicating with the inner cavity, and the delivery port is used for communicating with an external mechanism. A first chamber and a second chamber are formed in the inner cavity of the housing, the first chamber is used to store the liquid dispersant, the second chamber is used to store the dispersant, and the second chamber is used to store the dispersant. A chamber communicates with the delivery port. The first valve is used to control the connection between the first chamber and the second chamber. The first blocking part is used to control the connection between the delivery port and the external mechanism. The liquid delivery device is configured such that when the first valve is opened and the delivery port is blocked by the first blocking portion, the first chamber and the second chamber are communicated, so that the A liquid dispersant enters the second chamber and mixes with the dispersoid to form a dispersion. The liquid delivery device is further configured such that the pressure applying mechanism applies pressure to allow the dispersion system in the second chamber to pass through the delivery port after the first blocking portion is released from blocking the delivery port. A delivery port flows to and from the external mechanism.
即,所述液体输送装置的第一腔室预先存储有液体分散剂,所述第二腔室中预先存储有分散质,在需要配置所述分散系时,在预定条件下开启所述第一阀门即可使所述液体分散剂流入所述第二腔室中,并与所述分散质混合而形成分散系。然后连通所述输送口与所述外部机构,并通过压力施加机构加压,以迫使所述分散系流入所述外部机构并作用于目标位置。换句话说,利用该装置可一次性地完成所述分散系的配置和输送,整个过程无需额外借助其他容器或输送结构,避免在分散系中引入杂质。在医疗领域,所述液体分散剂能够使分散固体药剂而形成液体药剂,所述液体药剂可以是溶液状态、悬浊液状态、或乳浊液状态。所述分散质是指能够分散在所述液体分散剂中以得到液体药剂的固体药剂。That is, the liquid dispersant is pre-stored in the first chamber of the liquid delivery device, the dispersoid is pre-stored in the second chamber, and the first chamber is opened under predetermined conditions when the dispersion system needs to be configured. The valve allows the liquid dispersant to flow into the second chamber and mix with the dispersoid to form a dispersion. The delivery port is then communicated with the external mechanism and pressurized by a pressure applying mechanism to force the dispersion to flow into the external mechanism and act on the target location. In other words, the configuration and delivery of the dispersion system can be completed at one time by using this device, and the whole process does not require additional containers or delivery structures to avoid introducing impurities into the dispersion system. In the medical field, the liquid dispersant can disperse a solid drug to form a liquid drug, and the liquid drug can be in a solution state, a suspension state, or an emulsion state. The dispersoid refers to a solid pharmaceutical that can be dispersed in the liquid dispersion to obtain a liquid pharmaceutical.
本发明的目的之二在于提供一种治疗装置,所述治疗装置包括所述的液体输送装置、液体分散剂、固体药剂及球囊导管,所述液体分散系存储在所述第一腔室中,所述固体药剂存储在所述第二腔室中,所述球囊导管包括球囊和导管,所述导管的近端用于与所述输送口连通,所述球囊的远端与所述球囊的内部导通,所述球囊上还设有连接球囊内部与外部的微孔。该治疗装置中,所述固体药剂是纯药物或药物组合物,利用所述治疗装置可将所述固体药剂分散于所述分散剂中,以配置成液体药剂,并直接将所述液体药剂灌注至球囊,避免药剂污染。Another object of the present invention is to provide a treatment device, the treatment device includes the liquid delivery device, the liquid dispersion, the solid drug and the balloon catheter, and the liquid dispersion is stored in the first chamber , the solid medicament is stored in the second chamber, the balloon catheter includes a balloon and a catheter, the proximal end of the catheter is used to communicate with the delivery port, and the distal end of the balloon is connected to the The inside of the balloon is connected, and the balloon is also provided with micro-holes connecting the inside and the outside of the balloon. In the treatment device, the solid medicament is a pure drug or a pharmaceutical composition, and the solid medicament can be dispersed in the dispersant by the treatment device to form a liquid medicament, and the liquid medicament can be directly perfused to the balloon to avoid drug contamination.
为使本发明的目的、优点和特征更加清楚,以下结合附图对本发明作进一步详细说明。需说明的是,附图均采用非常简化的形式且均使用非精准的比例,仅用以方便、明晰地辅助说明本发明实施例的目的。附图中相同或相似的附图标记代表相同或相似的部件。In order to make the objects, advantages and features of the present invention clearer, the present invention will be further described in detail below with reference to the accompanying drawings. It should be noted that, the accompanying drawings are all in a very simplified form and in inaccurate scales, and are only used to facilitate and clearly assist the purpose of explaining the embodiments of the present invention. The same or similar reference numbers in the drawings represent the same or similar parts.
图1示出了一个优选实施例所提供的液体输送装置的结构示意图,图2示出了包括所述液体输送装置的治疗装置的结构示意图。Fig. 1 shows a schematic structural diagram of a liquid delivery device provided by a preferred embodiment, and Fig. 2 shows a structural schematic diagram of a treatment device including the liquid delivery device.
请参考图1及图2,所述液体输送装置包括壳体110、分割机构、第一阀门130、第一封堵部140以及压力施加机构150;所述壳体110具有一内腔,所述壳体110上设置有与所述内腔连通的输送口111,所述输送口111用于与一球囊导管200(即所述外部机构)连通。所述分割机构设置在所述内腔中,并将所述内腔分割为第一腔室112和第二腔室113,所述第一腔室112用于存储液体分散剂300,所述第二腔室113用于存储固体药剂400(即所述分散质),且所述第二腔室113与所述输送口111连通。所述第一阀门130设置在所述分割机构上,并用于控制所述第一腔室112与所述第二腔室113的通断。所述第一封堵部140用于可选择性地封堵所述输送口111。Please refer to FIG. 1 and FIG. 2 , the liquid delivery device includes a
所述液体输送装置被配置为当所述第一阀门130开启,以及所述第一封堵部140封堵所述输送口111后,所述第一腔室112和所述第二腔室113连通,使所述液体分散剂进入所述第二腔室113并与所述固体药剂400混合而形成液体药剂500(即所述分散系,如图6所示)。所述液体输送装置还被配置为当解除所述第一封堵部140对所述输送口111的封堵,且所述输送口111与所述球囊导管200连通后,所述压力施加机构施加压力,使所述第二腔室113中的所述液体药剂500通过所述输送口111流至所述球囊导管200并从所述球囊导管200流出,以作用于目标位置。The liquid delivery device is configured such that when the
本实施例所提供的液体输送装置100可用于完成液体药剂的配置,并可在不借助其他器械的情况下,直接与所述球囊导管200连接,将所述液体药剂500输送至球囊导管200,简化了液体药剂的转移过程,还避免在转移过程中污染液体药剂。本领域技术人员应知晓,所述球囊导管200包括球囊210和导管220,所述导管200的近端用于与所述输送口111连通,所述导管200的远端与所述球囊210连通。所述球囊210适于引入患者的脉管系统,例如冠状动脉、外周动脉或脉管系统的其他地方。所述球囊210的壁上贯穿地设置有多个微孔211,多个所述微孔211用于供所述液体药剂500流出并作用于所述目标位置。The
本实施例中,所述液体分散剂300可选自纯化水、生理盐水、造影剂等能够溶解或分散固体药剂的液体中的任一种或它们的混合液。所述固体药剂400可以是纯药物,也可以是纯药物与其他成分组成的药物组合物,所述其他成分可以是赋形剂、表面活性剂或稳定剂等中的至少一种。优选所述固体药物400为纯药物与其他成分组成的纳米药物颗粒,纳米药物颗粒包括胶束、脂质体等。所述固体药剂400的形态可以是粉末状、颗粒状、片状或以膜涂层形式涂覆在第二腔室113的腔壁上,所述固体药剂400还可以装载在胶囊壳中。本发明对所述固体药剂400的种类不做限定,具体根据实际需要选择。所述固体药剂400可以是抗增殖的药物、抗炎的药物、消炎的药物、抗增生的药物、抗菌的药物、抗肿瘤的药物、抗有丝分裂的药物、抑制细胞的药物、具有细胞毒的药物、抗骨质疏松的药物、抗血管生产的药物、抗在狭窄的药物、抑制微管的药物、抗转移的药物、或抗血栓的药物等。所述固体药剂400包括但不限于以下药物:地塞米松、波尼松龙、皮质酮、布地奈德、雌激素、柳氮磺吡啶、氨水杨酸、阿西美辛、七叶皂苷、氨基蝶呤、抗霉菌素、三氧化二砷、马兜铃酸、阿司匹林、小糪碱、银杏酚、雷帕霉素及其衍生物(包括佐他莫司、依维莫司、比欧莫斯、7-O-去甲基雷帕霉素、替西罗莫司、地磷莫司等)、内皮他汀、血管他汀、血管肽素、能够阻断平滑肌细胞增殖的单克隆抗体、左氧氟沙星、紫杉醇,多西紫杉醇,羟基喜树碱、长春花碱、长春新碱、阿霉素、5-氟尿嘧啶、顺铂、胸苷激酶抑制剂抗生素(特别是放线菌素-D)、激素、抗体治癌药物、双膦酸盐、选择性雌激素受体调节剂、雷尼酸锶、环孢霉素A、环孢霉素C及布雷菲德菌素A中的至少一种。In this embodiment, the
请继续参考图1,在一个示范性的实施例中,所述压力施加机构150设置在所述第一腔室112中,所述液体分散剂300存储在所述压力施加机构150与所述分割机构之间。当所述压力施加机构150向所述液体分散剂300施加压力,进而向所述第一阀门130施加压力至第一预定值时,所述第一阀门130开启。具体地,所述第一阀门130优选为单向阀,且所述单向阀被配置为在受到从所述第一腔室112指向所述第二腔室113的第一预定值的压力下开启,而在受到从所述第二腔室113指向所述第一腔室112的压力下保持关闭。如此设置,可保证所述液体分散剂300与所述固体药剂400在所述第二腔室113中混合以形成所述液体药剂500。单向阀的结构可以是现有技术中的常规设计,如具有切口的硅胶密封圈、挡板等。Please continue to refer to FIG. 1 , in an exemplary embodiment, the
所述第一阀门130的优选结构可参见图3,图示中的箭头表示液体分散剂300的流动方向。如图3所示,所述第一阀门130包括阀座131、第一封板132和第一弹性件133。所示分割机构上设置有通孔(图中未标注),所述阀座131设置在所述通孔处,并与所述通孔的孔壁连接。所述阀座131上设置有用于连通所述第一腔室112和所述第二腔室113的流体通道134,所述流体通道134的壁上设有台阶面。所述第一弹性件133设置在所述流体通道134内,其一端与所述流体通道134的壁连接,另一端与所述第一封板132连接。所述第一封板在所述第一弹性件133的作用下抵靠在所述台阶面上,以关闭所述流体通道;当所述第一封板132受到从所述第一腔室112指向所述第二腔室113的第一预定值的压力时,所述第一弹性件133变形以使所述第一封板132脱离所述台阶面而开启所述流体通道134,实现所述第一腔室112与所述第二腔室113的连通。本实施例中,所述台阶面朝向所述第二腔室113,且所述第一弹性件133靠近所述第二腔室113设置,当所述第一弹性件133受到压力时,所述第一弹性件133被压缩而使得所述流体通道134开启。在替代性的实施例中,所述第一弹性件133还可靠近所述第一腔室112设置,此时,所述第一弹性件133被拉伸而使得所述流体通道134开启。所述第一弹性件133包括但不限于弹簧,所述第一预定值根据所述第一弹性件133的具体种类及材料来确定,例如当所述第一弹性件133为弹簧时,所述第一预定值即根据所述弹簧的弹性系数来确定。可选地,本实施例所述压力施加机构150包括第一活塞151,所述第一活塞151在外力的作用下朝向所述液体分散剂300移动,以向所述液体分散剂300施加压力。所述压力施加机构150还可包括推杆152,所述推杆152设置在所述第一活塞151远离所述分割机构的一端,用于接受所述外力,并驱动所述第一活塞151移动。也即,在所述第一阀门130开启的情况下,所述压力施加机构150及所述第一腔室112构成类似于注射器的结构,方便操作、易于施加外力。The preferred structure of the
当所述压力施加机构150包括所述第一活塞151时,所述第一阀门130的结构还可如图4所示。此时,所述第一阀门130包括连接杆135和密封块136,连接杆135的一端与所述第一活塞151连接,另一端与所述密封块136连接。所述分割机构具有通孔,所述密封块136设置于所述通孔之中。当第一活塞151朝向所述分割机构移动时,所述第一活塞151推动所述连接杆135朝向所述第二内腔113移动,直至所述密封块136从通孔中移出,以使所述液体分散剂300可以通过分割机构中间的所述通道流入所述第二腔室113。进一步地,所述分割机构可以移动,当所述分割机构可移动时包括第二活塞120。所述压力施加机构150还用于向所述第二活塞120施加压力,并驱动所述第二活塞120朝向所述液体药剂移动,以向所述液体药剂500施加压力。详细而言,当所述第一腔室112中的液体分散剂300全部进入所述第二腔室113后,使用者向所述第一活塞151施加外力,所述第一活塞151朝向所述第二活塞120移动至所述第一活塞151与所述第二活塞120接触;继续向所述第一活塞151施加外力,所述第一活塞151驱动所述第二活塞120朝向所述液体药剂500移动,以迫使所述液体药剂500从所述输送口111流入所述球囊导管200,即所述压力施加机构150、所述第二活塞120与所述壳体110共同构成类似注射器的结构。本领域技术人员可理解,本实施例中所述第二活塞120与所述壳体110之间的摩擦力可以抵抗所述压力施加机构150向所述第一阀门130施加的第一预定值的压力,以避免所述第二活塞120在所述第一预定值的压力下移动,这在实际中可通过选择弹性系数合适的所述第一弹性件133来实现。When the
可选地,所述壳体111上还设置有刻度线,所述刻度线用于显示所述第二腔室113内所述液体药剂500的量以及所述第二活塞120的位置,便于判断所述液体输送装置100向所述球囊导管200所输送的液体药剂500的总量。Optionally, the
在本发明的进一步改进中,如图5所示,所述液体输送装置100还包括过滤机构160,所述过滤机构160例如是过滤膜,其设置在所述输送口111处,用于对液体药剂进行过滤,以阻止液体药剂500中较大粒径的颗粒物被输送至球囊导管200而进入脉管系统,避免对脉管系统造成栓塞。优选地,所述过滤膜上的滤孔孔径可以是1um(微米)-10um(微米),以允许粒径小于或等于10um的颗粒物进入球囊导管200。In a further improvement of the present invention, as shown in FIG. 5 , the
更进一步地,如图6及图7所示,所述液体输送装置100还包括第二封堵部170,设置在所述输送口111处,用于在所述液体药剂500受到的压力值超过第二预定值时封闭所述输送口111。利用所述第二封堵部170在所述液体药剂500的输送压力过大时封堵输送口111以暂停液体药剂的输送,避免过高的压力对脉管系统造成损伤。Further, as shown in FIG. 6 and FIG. 7 , the
详细而言,所述第二封堵部170包括第二封板171和第二弹性件172,所述第二弹性件172的一端与所述第二封板171连接,另一端与所述壳体111连接。所述压力施加机构170向所述液体药剂施加压力,并经所述液体药剂将压力传递至所述第二封板171上。当所述第二封板171受到的压力小于或等于所述第二预定值时,所述第二封板171远离所述输送口111,以保持所述输送口111开启(如图6所示),而当所述第二封板171受到的压力大于所述第二预定值时,所述第二弹性件172变形,并带动所述第二封板171朝向所述输送口111移动,直至封堵所述输送口111(如图6所示)。在使用者调整所述压力施加机构150,以使所述液体药剂500受到的压力小于或等于所述第二预定值时,所述第二弹性件172的形态恢复,并驱动所述第二封板171远离所述输送口111,使得所述输送口111重新开启,恢复液体药剂的输送。本实施例中,所述第二弹性件172设置在所述第二封板171靠近所述输送口111的一端,因此所述第二弹性件172被压缩变形,以驱动所述第二封板171移动并封堵所述输送口111。所述第二弹性件172包括但不限于弹簧,通过选择具有合适的弹性系数的弹簧即可实现上述目的。In detail, the
在替代性的实施例中,所述第一封堵部140包括第二阀门,所述液体输送装置还包括压力控制机构,所述压力控制机构被配置为监测所述液体药剂500所受到的压力,且当所述液体药剂500受到的压力大于所述第二预定值时控制所述第二阀门关闭以封堵所述输送口111。In an alternative embodiment, the
此外,为便于所述液体输送装置100与所述球囊导管200连接,所述液体输送装置100的所述输送口111及所述球囊导管200的导管220中的一个设有鲁尔公接头,另一个设有鲁尔母接头。In addition, in order to facilitate the connection between the
本领域技术人员可理解,前述对所述液体输送装置各个部件的介绍仅是所述液体输送装置实现的优选结构,其不应当本本发明构成限制。在其他实现方式中,所述第一阀门可以是电磁阀,且所述第一阀门还可与所述壳体的内壁直接相连,利用所述第一阀门将所述壳体的内腔分割为所述第一腔室和所述第二腔室,此时所述分割机构能够省略。通过通电的方式打开所述第一阀门,以及通过向所述第二腔室通入难溶性气体来向所述液体药剂施加压力,但该方案的液体输送装置在输送所述液体药剂时,所述壳体需始终保持竖直的状态,且配置的液体药剂的量多于实际需要的量,以避免气体进入血管。Those skilled in the art can understand that the foregoing description of each component of the liquid delivery device is only a preferred structure realized by the liquid delivery device, which should not be construed as a limitation of the present invention. In other implementation manners, the first valve may be a solenoid valve, and the first valve may also be directly connected to the inner wall of the casing, and the inner cavity of the casing is divided into two parts by the first valve. In the first chamber and the second chamber, the dividing mechanism can be omitted at this time. The first valve is opened by energizing, and pressure is applied to the liquid medicine by passing insoluble gas into the second chamber, but when the liquid delivery device of this scheme delivers the liquid medicine, the The casing should always be kept in a vertical state, and the amount of liquid medicine to be prepared is more than the actual required amount, so as to prevent gas from entering the blood vessel.
请返回参考图2,本发明实施例所提供的治疗装置包括前述的液体输送装置100、液体分散剂300、固体药剂400和球囊导管200。其中,所述液体分散剂300和所述固体药剂400可参考前述的介绍进行合理选择,此处不再赘述。所述球囊导管200包括球囊210和导管220,所述球囊210的壁上设有多个微孔211,所述导管220的近端用于与所述液体输送装置100的输送口111连通、远端与所述球囊210连通。所述液体分散剂300和所述固体药剂400在所述液体输送装置100的所述第二腔室113中混合形成液体药剂后,直接从所述输送口111处输送至球囊导管200,进而从所述球囊210上的微孔211流出,避免药剂污染。Referring back to FIG. 2 , the treatment device provided by the embodiment of the present invention includes the aforementioned
所述液体分散剂300与所述固体药剂400分散后可形成为溶液或悬浮液形式的液体药剂500。所述液体药剂500优选为稳定的悬浮液状态,且其中的药物颗粒为纳米级颗粒。可选地,所述悬浮液中的药剂颗粒尺寸在30nm-500nm,优选为35nm-300nm。After the
所述液体药剂500经所述导管220输送至所述球囊210后,从所述微孔211处流出并作用于目标位置。所述微孔211可均匀或不均匀地分别在所述球囊210的壁上。发明人进一步发现,当球囊210的壁上均匀地分布所述微孔211时,从不同位置的微孔211处流出的液体药剂500的流速和压力不一致,具体来说,从位于所述球囊210的近端的微孔211处流出的液体药剂500的流速和压力大于从所述球囊210的远端的微孔211处流出的液体药剂500的流速和压力。这样一来,从球囊210的近端微孔211处流出的液体药剂500很容易在血管近端(血管与球囊的近端相对于的位置)造成血肿和内皮脱落等损伤,并容易引起血管的痉挛,风险极大。为解决此问题,本实施例中优选所述球囊210的近端的微孔211的分布密度小于所述球囊210的远端的微孔211的分布密度,进一步优选位于所述球囊210的近端的微孔211的孔径小于位于所述球囊210的远端的微孔211的孔径。在示范性的实施例中,所述微孔211的孔径可在5um-50um范围内选择。After the
本实施例中,利用所述液体输送装置100配置液体药剂500,并完成所述液体药剂500的输送,在利用所述压力施加机构150向所述液体药剂500施加预定的压力来完成液体药剂的输送时,所述液体药剂500可从所述球囊210的所述微孔211处以4个大气压(0.608mpa)-16个大气压(1.62mpa)的压力流出。使用者还可通过控制压力施加机构150的加压速度和加压时间来控制输送至球囊导管200的液体药剂500的总量及用药时长。在一个典型性的实施例中,需要在15s-60s的时间内向目标位置使用总量为0.5ml-2ml的药剂总量,此时,当所述第一活塞151与所述分割机构接触后,根据所述壳体111的尺寸合理控制所述分割机构的移动速度,以使所述分割机构在预定时间内移动预定距离即可。优选,所述液体药剂在15s-30s的时间内使用完毕。In this embodiment, the
根据本发明实施例提供的技术方案,所述液体输送装置能够在完成液体药剂的配置后,直接将液体药剂输送至球囊导管并作用于目标位置,无需额外利用其它器械来就那些液体药剂的转移,避免液体药剂的污染。进一步地,利用压力施加机构完成液体药剂的输送时,通过在所述壳体上设置刻度,并调节加压速度,实现对液体药剂使用量及用药时长的控制。According to the technical solution provided by the embodiment of the present invention, the liquid delivery device can directly deliver the liquid medicine to the balloon catheter and act on the target position after the configuration of the liquid medicine is completed, without using other instruments to transfer the liquid medicine to the target position. Transfer to avoid contamination of liquid agents. Further, when the pressure applying mechanism is used to complete the delivery of the liquid medicine, by setting a scale on the casing and adjusting the pressurization speed, the control of the usage amount and the duration of the liquid medicine is realized.
虽然本发明披露如上,但并不局限于此。本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样,倘若本发明的这些修改和变型属于本发明及其等同技术的范围之内,则本发明也意图包含这些改动和变型在内。Although the present invention is disclosed above, it is not limited thereto. Various modifications and variations can be made in the present invention by those skilled in the art without departing from the spirit and scope of the invention. Thus, provided that these modifications and variations of the present invention fall within the scope of the present invention and its technical equivalents, the present invention is also intended to include such modifications and variations.
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010833882.5A CN111840763A (en) | 2020-08-18 | 2020-08-18 | Liquid conveying device and treatment device |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010833882.5A CN111840763A (en) | 2020-08-18 | 2020-08-18 | Liquid conveying device and treatment device |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111840763A true CN111840763A (en) | 2020-10-30 |
Family
ID=72970286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010833882.5A Pending CN111840763A (en) | 2020-08-18 | 2020-08-18 | Liquid conveying device and treatment device |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111840763A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112245784A (en) * | 2020-11-09 | 2021-01-22 | 上海微创医疗器械(集团)有限公司 | Medical delivery device and drug delivery system |
CN113926061A (en) * | 2021-11-18 | 2022-01-14 | 苏州海宇新辰医疗科技有限公司 | Balloon catheter |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101175519A (en) * | 2005-05-16 | 2008-05-07 | 马林克罗特公司 | Multi-stage syringe and methods of using the same |
CN101502687A (en) * | 2008-02-04 | 2009-08-12 | 龚静山 | Monotubular double-chamber syringe needle cylinder and injection method thereof |
KR20110041826A (en) * | 2009-10-16 | 2011-04-22 | 조희민 | Syringes with check valves for heterogeneous liquid mixing |
US20110160575A1 (en) * | 2008-09-02 | 2011-06-30 | By-Pass, Inc. | Microporous balloon catheter |
US20110218494A1 (en) * | 2008-11-12 | 2011-09-08 | Gerrans Lawrence J | Multi-Balloon Catheter for Extravasated Drug Delivery |
TW201521809A (en) * | 2013-08-30 | 2015-06-16 | Glucago Llc D B A Lyogo | Plunger and plunger valve for drug delivery |
US20150343153A1 (en) * | 2012-12-20 | 2015-12-03 | Christopher J. Granelli | Dual chamber mixing syringes and methods of using same |
CN107206165A (en) * | 2014-12-24 | 2017-09-26 | 弗罗桑医疗设备公司 | Syringe for keeping and mixing the first and second materials |
US20170333632A1 (en) * | 2016-05-23 | 2017-11-23 | Olivia Arrendondo | Multi-Chamber Syringes And Methods For Using The Same |
US20180093040A1 (en) * | 2016-09-30 | 2018-04-05 | Thorne Consulting And Intellectual Property, Llc | Multiple chamber syringe piston and mixing devices |
CN110177588A (en) * | 2016-11-18 | 2019-08-27 | Om有限公司 | Package and apparatus for mixing pharmaceutical substances |
US20190351150A1 (en) * | 2017-01-19 | 2019-11-21 | Tecnedil International S.R.L. | A safety syringe having a retracting needle and being pre-fillable with two active ingredients |
CN212416641U (en) * | 2020-08-18 | 2021-01-29 | 上海微创医疗器械(集团)有限公司 | Liquid conveying device and treatment device |
-
2020
- 2020-08-18 CN CN202010833882.5A patent/CN111840763A/en active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101175519A (en) * | 2005-05-16 | 2008-05-07 | 马林克罗特公司 | Multi-stage syringe and methods of using the same |
CN101502687A (en) * | 2008-02-04 | 2009-08-12 | 龚静山 | Monotubular double-chamber syringe needle cylinder and injection method thereof |
US20110160575A1 (en) * | 2008-09-02 | 2011-06-30 | By-Pass, Inc. | Microporous balloon catheter |
US20110218494A1 (en) * | 2008-11-12 | 2011-09-08 | Gerrans Lawrence J | Multi-Balloon Catheter for Extravasated Drug Delivery |
KR20110041826A (en) * | 2009-10-16 | 2011-04-22 | 조희민 | Syringes with check valves for heterogeneous liquid mixing |
US20150343153A1 (en) * | 2012-12-20 | 2015-12-03 | Christopher J. Granelli | Dual chamber mixing syringes and methods of using same |
TW201521809A (en) * | 2013-08-30 | 2015-06-16 | Glucago Llc D B A Lyogo | Plunger and plunger valve for drug delivery |
CN107206165A (en) * | 2014-12-24 | 2017-09-26 | 弗罗桑医疗设备公司 | Syringe for keeping and mixing the first and second materials |
US20170333632A1 (en) * | 2016-05-23 | 2017-11-23 | Olivia Arrendondo | Multi-Chamber Syringes And Methods For Using The Same |
US20180093040A1 (en) * | 2016-09-30 | 2018-04-05 | Thorne Consulting And Intellectual Property, Llc | Multiple chamber syringe piston and mixing devices |
CN110177588A (en) * | 2016-11-18 | 2019-08-27 | Om有限公司 | Package and apparatus for mixing pharmaceutical substances |
US20190351150A1 (en) * | 2017-01-19 | 2019-11-21 | Tecnedil International S.R.L. | A safety syringe having a retracting needle and being pre-fillable with two active ingredients |
CN212416641U (en) * | 2020-08-18 | 2021-01-29 | 上海微创医疗器械(集团)有限公司 | Liquid conveying device and treatment device |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112245784A (en) * | 2020-11-09 | 2021-01-22 | 上海微创医疗器械(集团)有限公司 | Medical delivery device and drug delivery system |
CN113926061A (en) * | 2021-11-18 | 2022-01-14 | 苏州海宇新辰医疗科技有限公司 | Balloon catheter |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10806909B2 (en) | Balloon catheter systems for delivery of dry drug delivery vesicles to a vessel in the body | |
Stevenson et al. | Reservoir-based drug delivery systems utilizing microtechnology | |
CN104039371B (en) | For the improved formulations of medication coat medical treatment device | |
EP1986727B1 (en) | Catheter with porous Balloon | |
US20200101269A1 (en) | Apparatus and methods for scaffolding | |
US20160256611A1 (en) | Drug Delivery Device | |
US8911425B2 (en) | Electronic pill comprising a medicine reservoir | |
KR102338079B1 (en) | Drug delivery systems and methods for treatment of bladder cancer with gemcitabine | |
CN111840763A (en) | Liquid conveying device and treatment device | |
JP2010535074A (en) | Improved drug-coated medical products, their manufacture and use | |
CN107375238A (en) | A kind of superelevation medicine-carried nano particles and preparation method thereof | |
CN113521505B (en) | Balloon catheter and preparation method thereof | |
CN212416641U (en) | Liquid conveying device and treatment device | |
CN106621001A (en) | Recyclable drug balloon catheter | |
CN214485274U (en) | Balloon dilation catheter and drug delivery device | |
US8771257B2 (en) | Drug delivery sheath | |
US10967122B2 (en) | Subcutaneous drug delivery device with manual activation and deactivation of drug release | |
WO2008088536A8 (en) | Differential drug release from a medical device | |
WO2022095791A1 (en) | Medical delivery device and drug delivery system | |
CN214485280U (en) | Medical delivery device and drug delivery system | |
US20220127559A1 (en) | Microrobot and Method of Manufacturing the Microrobot | |
CN216456481U (en) | Drug-loaded balloons and balloon catheters | |
Chandel | Devices for Controlled Release Advancements and Effectiveness | |
EP4070825A1 (en) | Drug-loaded implantable medical instrument and manufacturing method therefor | |
US20200353233A1 (en) | Non-digestible, controlled release system for soluble drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |